It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But
Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first
quarter.
The CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company’s fast-growing DailyMed
service.
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
Greenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein
business.
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local doctors.
MD Logistics has completed a coldstorage facility for pharmaceutical products in its hometown of Plainfield.
Lilly executives want to make biotech their top focus.
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
